YUHSpace: Dept. of Obstetrics and Gynecology (산부인과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Obstetrics and Gynecology (산부인과학교실)

Dept. of Obstetrics and Gynecology (산부인과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

MicroRNA expression profiles in serous ovarian carcinoma

Eun Ji Nam ; Heejei Yoon ; Sang Wun Kim ; Hoguen Kim ; Young Tae Kim ; Jae Ho... CLINICAL CANCER RESEARCH, Vol.14(9) : 2690-2695, 2008

PDF

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial o...

HanByoul Cho ; Hye Won Hur ; Sang Wun Kim ; Sung Hoon Kim ; Jae Hoon Kim ; Yo... CANCER IMMUNOLOGY IMMUNOTHERAPY, Vol.58(1) : 15-23, 2009

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expr...

Funda Meric-Bernstam ; Vicky Makker ; Ana Oaknin ; Do-Youn Oh ; Susana Banerj... JOURNAL OF CLINICAL ONCOLOGY, Vol.42(1) : 47-58, 2024-01

PDF

This table browses all dspace content
Issue Date	Title	Journal Title
2024	Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement	JOURNAL OF GYNECOLOGIC ONCOLOGY
2024	Clinical relevance of vaginal natural orifice transluminal endoscopic surgery (vNOTES) in gynecology	Obstetrics & Gynecology Science
2024	Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines	JOURNAL OF GYNECOLOGIC ONCOLOGY
2024	Maternal PM2.5 exposure is associated with preterm birth and gestational diabetes mellitus, and mitochondrial OXPHOS dysfunction in cord blood	ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
2024	Shear stress in the intervillous space promotes syncytial formation of iPS cells-derived trophoblasts	BIOLOGY OF REPRODUCTION
2024	Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125	GYNECOLOGIC ONCOLOGY
2024	Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer	CANCER RESEARCH
2024	Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045	INTERNATIONAL JOURNAL OF CANCER
2024	Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial	JOURNAL OF CLINICAL ONCOLOGY
2024	Development and validation of artificial intelligence-based analysis software to support screening system of cervical intraepithelial neoplasia	SCIENTIFIC REPORTS
2024	Effects of hormone replacement therapy on bone mineral density in Korean adults With Turner syndrome	JOURNAL OF KOREAN MEDICAL SCIENCE
2024	Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines	JOURNAL OF GYNECOLOGIC ONCOLOGY
2024	Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial	JOURNAL OF CLINICAL ONCOLOGY
2024	Lugol's Solution Reduces Positive Margins and Residual Disease After the Large Loop Excision of Transformation Zone	JOURNAL OF LOWER GENITAL TRACT DISEASE
2024	Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study	CLINICAL CANCER RESEARCH
2023	Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer	GLAND SURGERY
2023	Tibolone and Breast Cancer	Journal of Menopausal Medicine
2023	Extrauterine Undifferentiated Uterine Sarcoma Arising from Bladder Endometriosis in a Postmenopausal Woman: A Case Report	Journal of Menopausal Medicine
2023	Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045	INTERNATIONAL JOURNAL OF CANCER
2023	Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial	LANCET ONCOLOGY